NCT06910839View on ClinicalTrials.gov

Study to Learn About How the Study Medicines Called PF-07976016 and PF-06882961 Are Taken Up by the Body, and if Either of Them Change How the Body Processes the Other Medicine in Otherwise Healthy Adults With Overweight or Obesity

PHASE1TerminatedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

March 13, 2025

Primary Completion Date

May 1, 2025

Study Completion Date

May 20, 2025

Conditions
OverweightObesity
Interventions
DRUG

PF-07976016

PF-07976016 oral tablets

DRUG

PF-06882961

PF-06882961 oral tablets

Trial Locations (1)

92801

Anaheim Clinical Trials, LLC, Anaheim

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT06910839 - Study to Learn About How the Study Medicines Called PF-07976016 and PF-06882961 Are Taken Up by the Body, and if Either of Them Change How the Body Processes the Other Medicine in Otherwise Healthy Adults With Overweight or Obesity | Biotech Hunter | Biotech Hunter